[Skip to Content]
[Skip to Content Landing]
Correspondence
September 20, 2010

Exudative, Nonhealing Scalp: A Complication of Systemic Chemotherapy With Capecitabine and Bevacizumab

Author Affiliations
 

Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2011

Arch Dermatol. 2011;147(1):134-135. doi:10.1001/archdermatol.2010.396

Capecitabine, a prodrug of fluorouracil, is a pyrimidine analogue that can inflame actinic keratoses.1 The inflammation manifests primarily as simple erythema in areas of actinic keratoses, although acral erythema and other cutaneous adverse effects have been reported.1,2 Bevacizumab inhibits angiogenesis by blocking vascular endothelial growth factor and can produce cutaneous adverse effects such as exfoliative dermatitis, skin ulceration, and acneiform eruptons.3 We describe a severe complication resulting from the combination of capecitabine and bevacizumab.

×